DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)

DNAtrix

Status and phase: Completed; Phase 1

Conditions: Glioblastoma or Gliosarcoma

Treatments: Drug: Interferon-gamma; Drug: Single intratumoral injection of DNX-2401

Study type: Interventional

Funder types: Industry

Identifiers

NCT02197169

2401BT-IFN-001

Details and patient eligibility

About

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant primary brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase Ib study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified, conditionally replicative and oncolytic human-derived adenovirus. DNX-2401 is delivered directly into the tumor where it may establish an active infection by replicating in and killing tumor cells.

Full description

Enrollment has been completed for the randomized portion of the study with ongoing evaluation of tumor response and safety. No additional subjects will be randomized or receive interferon gamma (IFN-γ).

The non-randomized portion of the study is open for screening and enrollment. Eligible subjects will receive a single intratumoral injection of DNX-2401 into a recurrent glioblastoma or gliosarcoma brain tumor using the Alcyone MEMS Cannula (AMC™) System (cannula). Tumor response and safety will be evaluated.

After receiving DNX-2401, subjects will return to the clinic for study visits at regular intervals for safety monitoring, MRI scans and other assessments for up to 18 months. Thereafter, they will be followed closely for safety and survival.

Enrollment: 37 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Glioblastoma or gliosarcoma in first or second recurrence only
• Documented tumor recurrence or progression after failing prior surgical resection, chemotherapy, or radiation
• Tumor size greater than or equal to 1.0 cm in two perpendicular diameters
• Not undergoing surgical resection or for whom gross total resection is not possible
• Karnofsky Performance Status greater than or equal to 70%

Exclusion criteria

• Multiple intracranial malignant glioma lesions
• Tumor location or involvement that would result in risk of ventricular penetration during tumor injection
• Tumor involving both hemispheres or that which involves the subependyma or suspected cerebrospinal fluid dissemination
• Tumor involving brain stem
• Documented extracranial metastasis
• Inability to undergo MRI
• Pregnant or nursing females
• Any medical condition that precludes the surgery necessary to administer DNX-2401 into the tumor using the cannula
• Immunocompromised subjects or those with autoimmune conditions, active hepatitis or positive for human immunodeficiency virus (HIV)
• Li-Fraumeni Syndrome

Other protocol-defined inclusion/exclusion criteria may apply as outlined in the relevant protocol version

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

37 participants in 2 patient groups

DNX-2401 alone

Experimental group

Description:

Single intratumoral injection of DNX-2401

Treatment:

Drug: Single intratumoral injection of DNX-2401

DNX-2401 + Interferon gamma (IFN-γ)

Experimental group

Description:

Interferon gamma (IFN-γ) beginning at Day 14

Treatment:

Drug: Single intratumoral injection of DNX-2401

Drug: Interferon-gamma